Kestra Medical Technologies Files for IPO

TL;DR

Kestra Medical just filed for IPO, get ready for some new medtech stock!

AI Summary

Kestra Medical Technologies, Ltd. filed an S-1 registration statement with the SEC on February 10, 2025, indicating its intent to go public. The company, headquartered in Kirkland, Washington, operates in the surgical and medical instruments sector. This filing is a preliminary step before offering its shares to the public.

Why It Matters

This S-1 filing signals Kestra Medical Technologies' intention to become a publicly traded company, which could lead to increased capital for expansion and innovation in the medical device industry.

Risk Assessment

Risk Level: medium — As a company filing for an IPO, Kestra Medical Technologies is in the early stages of public trading, carrying inherent risks associated with new market entrants and the medical device sector.

Key Numbers

• 98033 — ZIP Code (Kestra Medical's principal business and mail address is in Kirkland, Washington.)
• (425) 279-8002 — Phone Number (This is the business and mail phone number for Kestra Medical Technologies.)

Key Players & Entities

• KESTRA MEDICAL TECHNOLOGIES, LTD. (company) — Registrant
• Brian Webster (person) — Chief Executive Officer
• Sophia Hudson (person) — Legal Counsel
• Christie W.S. Mok (person) — Legal Counsel
• 3841 (dollar_amount) — Standard Industrial Classification Code
• 333-284807 (dollar_amount) — SEC File Number

FAQ

Key Financial Figures

• $1.3 billion — 2001, global WCD revenues have grown to $1.3 billion in 2023, with approximately 85% of the
• $3,436 — average Medicare reimbursement rate of $3,436 per patient per month, we believe this
• $10 billion — elieve this represents an approximately $10 billion annual addressable market. In select in
• $3,000 — estimated average reimbursement rate of $3,000 per patient per month derived from indu
• $14 billion — elieve this represents an approximately $14 billion total annual market opportunity outside

Filing Documents

• d744414ds1.htm (S-1) — 2405KB
• d744414dex31.htm (EX-3.1) — 23KB
• d744414dex32.htm (EX-3.2) — 16KB
• d744414dex51.htm (EX-5.1) — 21KB
• d744414dex106.htm (EX-10.6) — 103KB
• d744414dex107.htm (EX-10.7) — 102KB
• d744414dex108.htm (EX-10.8) — 102KB
• d744414dex109.htm (EX-10.9) — 120KB
• d744414dex1010.htm (EX-10.10) — 13KB
• d744414dex211.htm (EX-21.1) — 3KB
• d744414dex231.htm (EX-23.1) — 2KB
• d744414dex232.htm (EX-23.2) — 2KB
• d744414dexfilingfees.htm (EX-FILING FEES) — 28KB
• g744414g0206062939804.jpg (GRAPHIC) — 4KB
• g744414g0206062940178.jpg (GRAPHIC) — 11KB
• g744414g0206062940647.jpg (GRAPHIC) — 2KB
• g744414g0206062941860.jpg (GRAPHIC) — 2KB
• g744414g0206063100264.jpg (GRAPHIC) — 2KB
• g744414g10t05.jpg (GRAPHIC) — 62KB
• g744414g16a16.jpg (GRAPHIC) — 157KB
• g744414g34h43.jpg (GRAPHIC) — 158KB
• g744414g34r82.jpg (GRAPHIC) — 2KB
• g744414g62z73.jpg (GRAPHIC) — 54KB
• g744414g89x91.jpg (GRAPHIC) — 113KB
• 0001193125-25-023649.txt ( ) — 3688KB

RISK FACTORS

RISK FACTORS 22 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 88 ORGANIZATIONAL TRANSACTIONS 90

USE OF PROCEEDS

USE OF PROCEEDS 93 DIVIDEND POLICY 94 CAPITALIZATION 95

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 99

BUSINESS

BUSINESS 120 MANAGEMENT 160

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 166 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 174 PRINCIPAL SHAREHOLDERS 176 DESCRIPTION OF CERTAIN INDEBTEDNESS 178 DESCRIPTION OF SHARE CAPITAL 180 SHARES ELIGIBLE FOR FUTURE SALE 191 BERMUDA COMPANY CONSIDERATIONS 194 MATERIAL BERMUDA, IRISH AND U.S. FEDERAL INCOME TAX CONSIDERATIONS 201

UNDERWRITING

UNDERWRITING 211 LEGAL MATTERS 220 EXPERTS 220 WHERE YOU CAN FIND ADDITIONAL INFORMATION 220 EXCHANGE CONTROLS 220 ENFORCEMENT OF CIVIL LIABILITIES UNDER U.S. FEDERAL SECURITIES LAWS 221 INDEX TO FINANCIAL STATEMENTS F-1 We are responsible for the information contained in this prospectus and in any free writing prospectus we prepare or authorize. We have not, and the underwriters have not, authorized anyone to provide you with different information, and we and the underwriters take no responsibility for any other information others may give you. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the cover of this prospectus. Persons who come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. i Table of Contents BASIS OF PRESENTATION Kestra Medical Technologies, Ltd., the issuer in this offering, was incorporated on May 20, 2021 in connection with this offering to serve as a holding company for its subsidiaries, and it has not engaged in any business or other activities other than those incidental to its formation, the organizational transactions described herein and the preparation of this prospectus and the registration statement of which this prospectus forms a part. Following this offering and the consummation of the organizational transactions, Kestra Medical Technologies, Ltd. will remain a holding company, and it will operate and control all of the business and affairs and consolidate the financial results of West Affum Intermediate Holdings Co

forward-looking statements in this prospectus. See Special Note Regarding Forward-Looking Statements

forward-looking statements in this prospectus. See Special Note Regarding Forward-Looking Statements. Certain information in the text of this prospectus is contained in independent industry publications. The source of these independent industry publications is provided below. These independent industry publications do not form part of this prospectus and are not incorporated by reference herein. The New England Journal of Medicine, Wearable Cardioverter-Defibrillator after Myocardial Infarction, September 2018 (the New England Journal of Medicine Study); American Heart Association, Abstract 4141304: Clinical Impact of Ventricular and Supraventricular Arrhythmia Detection with a Novel Wearable Cardioverter Defibrillator, November 2024; American Heart Association, Abstract 4141488: Initial Real-World Experience with a Novel Wearable Cardioverter Defibrillator, November 2024; iii Table of Contents American Heart Association, Heart Disease and Stroke Statistics 2023 Update: A Report From the American Heart Association, February 2023; American Heart Association, Left Ventricular Ejection Fraction Assessment Among Patients with Acute Myocardial Infarction and Its Association with Hospital Quality of Care and Evidence-Based Therapy Use, September 2012; American Heart Association, Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014), July 2018; American Heart Association, 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association, February 2024; European Heart Journal, 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure, May 2016; Heart Failure Society of America, HF Stats 2024: Heart Failure Epidemiology and Outcomes Statistics, September 2024; JAMA, Heart Failure with Reduced Ejection FractionA Review, August 2020; Journal of Cardiovascular Electrophysiology, Impact of Wearable Cardioverter-Defibrillato

View Full Filing

View this S-1 filing on SEC EDGAR